House Ways and Means Committee hears Utah testimony urging federal support for medical innovation and patient access

The House Ways and Means Committee held a listening session in Salt Lake City to hear public testimony on promoting medical innovation and ensuring equitable access to clinical trials and advanced treatments, public commenters told the panel.

Commenters said the issue matters because federal policies can either encourage or hinder new medical research and the ability of patients—particularly those in rural areas—to access cutting‑edge care.

"The Ways and Means Committee is in Salt Lake City to listen and learn directly from Americans, making the next generation of medicines and the patients who are benefiting from those breakthroughs to see what Congress can do to encourage medical innovation in America," Commenter 1, a commenter, told the panel.

Another commenter said Utah has "some of the most innovative and fastest growing life science sectors in the country," and argued that local innovation helps reduce costs and expand care. "Utah has some of the most innovative and fastest growing life science sectors in the country, creating innovation that is not gonna stymie our ability to not only lower cost, but provide care for those that need it," Commenter 2 said.

A separate witness framed the goal as keeping clinical research and trials in the United States: "Our innovations transform patient care, improve outcomes, and give hope. Ensuring critical, cutting edge clinical studies are conducted in The United States should be a core tenant of our government's agenda," Commenter 3 said.

One speaker described a personal case to illustrate the stakes. "Our unborn son was diagnosed with bilateral renal agenesis, a universally fatal condition with no treatment options. Our little Isaac is now nearly 3 years old and active on kidney recipient list of multiple regions," Commenter 4 said, and asked the committee to "keep working to ensure that every American has an equitable opportunity to receive this type of innovative care in their most dire moments."

Commenters also emphasized access barriers for geographically distant patients. "30 percent of our patients that are in clinical trials come from far away, from rural and frontier, regions," Commenter 5 said, adding that innovations such as telehealth visits, local coordination of care and remote administration of treatments have improved management and quality of life for those patients.

Speakers cautioned that favorable state policies can be undermined by federal rules. "Government's laws and regulations can promote or impede innovation. In Utah, we are very fortunate to have a state government that supports our industry. However, no matter how favorable the state's innovation landscape, misguided federal policies can erode any home team advantage," Commenter 6 said, urging congressional action to "unleash the full potential of life sciences innovation in Utah and beyond."

The session recorded testimony and did not include any formal votes or Committee directives; the transcript does not specify next steps for legislation or rule changes.